CCTG Clinical Trials
Public Trial Select
Member Trial Select
TAILORx | MAC12 trial showed no benefit from chemotherapy for many women with breast cancerClinical trials are not always about finding a new drug that works but sometimes challenge current standards of care that may help spare patients unnecessary treatment. More >> |
Recently Activated Trials
Member Links
CCTG’s MA.39 trial receives green light from funding bodiesOne of the most promising advances in cancer treatment is the use of biological markers or biomarkers to identify the therapies a particular cancer may or may not respond to. More >> |
Planned Trials
Committees Select
Group newsletter: CCTG Connection
April 22, 2020
 A guest editorial first published in the "Cancer Letter"
While the National Clinical Trials Network (NCTN) groups remain open for business during the pandemic, it’s not business as usual. For good reason, clinical trials are taking a backseat to clinical care. Leadership and members themselves face significant challenges treating oncology patients, as attention and resources are diverted to minister to those with COVID-19. Read More |
 IND.216: a phase II study of buparlisib and associated biomarkers, raptor and p70S6K, in patients with relapsed and refractory chronic lymphocytic leukemia Sarit Assouline, Lilian Amrein, Raquel Aloyz, Versha Banerji, Stephen Caplan, Carolyn Owen, Wanda Hasegawa, Sue Robinson, Sudeep Shivakumar, Anca Prica, Anthea Peters, Linda Hagerman, Laura Rodriguez, Tanya Skamene, Lawrence Panasci, Bingshu E. Chen & Annette E. Hay Read More |
April 08, 2020
 The CCTG BR31 (NCT02273375) trial, A Phase III Prospective Double Blind Placebo Controlled Randomized Study of Adjuvant MEDI4736 in Completely Resected Non-Small Cell Lung Cancer has been closed to accrual to the main study. The purpose of this study was to find out whether it is better to receive a new drug, MEDI4736, or better to receive no further treatment after surgery (and possibly chemotherapy) for lung cancer. Read More |
 This past week the central office has continued to support CCTG network activities including addressing impacts of COVID-19. CCTG regulatory/ethics compliance and trial teams rolled out COVID-19 addenda for all trials. These addenda have been added to all CCTG trial pages to support sites and trial teams in our network. We are also incorporating an EDC form for the collection of COVID-19 information for designated trials. Read More |
Patient information on cancer clinical trials and COVID-19 (Coronavirus)Published: April 08, 2020Category: News  As the health care systems in Canada ramp up to meet the coming COVID-19 (Coronavirus) challenges, the Canadian Cancer Trials Group (CCTG) recognizes that this may have an impact on the conduct and availability of cancer clinical trials. People living with cancer are at an increased risk from COVID-19 because of underlying medical conditions and a compromised immune system. Patient care, safety and well-being are a priority while we work to minimize the impact and duration of this pandemic. Read More |
COVID-19 studies in development: An overviewPublished: April 08, 2020Category: Office of the Director  Dear Colleagues: Across the country, people, patients and health care providers have been directly impacted by preparations and managing the effects of the COVID pandemic. We have all worked to implement measures to reduce risk of infection even as we have tried to maintain the best care for patients with cancer. For CCTG, we have defined the following priorities Read More |
March 27, 2020
CCTG critical research continues in remote work environmentPublished: March 27, 2020Category: Group updates CCTG and its scope of research has been deemed an essential service by Queen’s University and we continue to be operational for our sites and trial patients. Given the critical nature of our research, we continue to monitor our activities and how trial adjustments can be made to ensure that patients can be managed on protocols. The CCTG Operations and Statistics Centre has successfully completed the transition to a remote work environment with a small number of support staff in the offices. Read More |
March 20, 2020
COVID-19 update: CCTG remains open and opperationalPublished: March 20, 2020Category: Office of the Director As the COVID-19 situation continues to evolve, CCTG is closely monitoring the situation in consultation with our network of investigators and trial staff. The CCTG Operations and Statistical Centre remains operational and has full capabilities to support trial develop and oversight of the current portfolio.For the safety of our community we have completed a transition to remote work for our staff. Read More |